Citations

Clear

78 citation(s) found for "Sledge, George".

Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith , Asmann, Yan W. , Eckel‐Passow, Jeanette E. , Tenner, Kathleen , Jen, Jin , Fan, Jian‐Bing , Geiger, Xochiquetzal J., McCullough, Ann E. , Chen, Beiyun, Zschunke, Michael A., Jenkins, Robert B. , Reinholz, Monica M., Kalari, Krishna R. , Dueck, Amylou C. , Sledge, George W. , Winer, Eric P. , Gralow, Julie R. , Ballman, Karla V.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 509-509

10.1200/jco.2014.32.15_suppl.509 Get It

Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.
O’Neill, Anne, Dang, Chau T. , Northfelt, Donald W. , Gradishar, William J. , Goldstein, Lori J. , Brufsky, Adam , Bloom, Stuart H. , Fox, Kevin R., Hendricks, Carolyn B., Balcueva, Ernie, Brufsky, Adam M , Miller, Kathy D. , Mayer, Ingrid A. , Sparano, Joseph A. , Tevaarwerk, Amyé , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 500-500

10.1200/jco.2014.32.15_suppl.500 Get It

A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.
O’Neill, Anne, Schneider, Bryan P. , Flockhart, David A., Skaar, Todd C. , Liu, Minetta C. , Lohrisch, Caroline , Sologuren, Carlos Vallejos, Villa, Diego , Silverman, Paula , Cheema, P. , Moore, Dennis F., Stearns, Vered , Goetz, Matthew P. , Sparano, Joseph A. , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 546-546

10.1200/jco.2016.34.15_suppl.546 Get It

Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.
Ramanathan, Ramesh K., Wang, Lan , Fan, Xiaolin , Motwani, Monica, Wong, Shekman, Morgan-Lappe, Susan E. , Iyer, Suhasini , Naumovski, Louie, Gordon, Michael S. , Nemunaitis, John , Sledge, George W. , Strickler, John H.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2507-2507

10.1200/jco.2016.34.15_suppl.2507 Get It

Symptom burden and employment status in breast cancer (BC) survivors.
Luis, Inês Maria Vaz Duarte, O’Neill, Anne, Sepucha, Karen , Dang, Chau T. , Northfelt, Donald W. , Schneider, Bryan P. , Miller, Kathy D. , Winer, Eric P. , Sledge, George W. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 10073-10073

10.1200/jco.2018.36.15_suppl.10073 Get It

The association of early toxicity and outcomes for patients treated with abemaciclib.
Forrester, Tammy , Frenzel, Martin, Cox, Joanne, Barriga, Susana , Tolaney, Sara M. , Rugo, Hope S. , Sledge, George W. , Johnston, Stephen , Goetz, Matthew P. , Martín, Miguel , Toi, Masakazu

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1053-1053

10.1200/jco.2018.36.15_suppl.1053 Get It

Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.
Neven, Patrick , Tolaney, Sara M. , Barriga, Susana , Rugo, Hope S. , Iwata, Hiroji , Toi, Masakazu , Goetz, Matthew P. , Kaufman, Peter A. , Lin, Yong , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1002-1002

10.1200/jco.2018.36.15_suppl.1002 Get It

Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.
Tolaney, Sara M. , Campone, Mario , Barriga, Susana , Leo, Angelo Di , Llombart‐Cussac, Antonio , Dickler, Maura N. , Iwata, Hiroji , Toi, Masakazu , Kaufman, Peter A. , André, Valérie , Goetz, Matthew P. , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 1048-1048

10.1200/jco.2018.36.15_suppl.1048 Get It

Abstract CT099: The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3
O’Shaughnessy, Joyce , Forrester, Tammy , Goetz, Matthew P. , Sledge, George W. , Martín, Miguel , Lin, Yong , Smith, Ian C., Leo, Angelo Di , Johnston, Stephen

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: CT099-CT099

10.1158/1538-7445.am2018-ct099 Get It

Abstract Background: A recent exploratory subgroup analysis pooling data from over 1000 patients (pts) in MONARCH 2 (final analysis) and MONARCH 3 (interim analysis) demonstrated that pts with clinical characteristics that predict for worse outcome (e.g. liver metastases, progesterone receptor [PgR]-negative status, high-grade tumors) received the largest benefit from the addition of abemaciclib to endocrine therapy (ET). There is also interest in determining the extent to which abemaciclib improves progression-free survival (PFS) in pts with favorable prognostic factors (e.g. bone-only disease, long treatment-free interval [TFI]). Here we present an update of the subgroup analyses of the MONARCH 3 study using data from the preplanned final PFS analysis. Methods: Enrollment criteria and study designs were previously described (Sledge et al. J Clin Oncol. 2017; Goetz et al. J Clin Oncol. 2017). An exploratory pooled analysis was conducted using data from MONARCH 2 (NCT02107703) and the MONARCH 3 (NCT02246621) preplanned final PFS analysis to identify significant prognostic factors regardless of therapy received. Using the updated MONARCH 3 data, PFS and objective response rate (ORR) (in pts with measurable disease) were examined within the prognostic subgroups that had been previously identified as being statistically significant. Additionally, subpopulation treatment effect pattern plot (STEPP) methodology was used to evaluate the association between TFI following adjuvant ET and outcomes of NSAI alone or with abemaciclib. Results: Assessment of clinical factors from MONARCH 2 and MONARCH 3 (final PFS data) confirmed that the following factors remained significantly prognostic regardless of treatment received: bone-only disease, liver metastases, tumor grade, PgR status, and ECOG performance status. In MONARCH 3, prognosis was poor in pts with liver metastases, PgR-negative tumors, and high-grade tumors. While all subpopulations benefited from the addition of abemaciclib to ET regardless of prognosis, pts with these three poor prognostic factors received substantial benefit from abemaciclib, with PFS hazard ratios (HR) ranging from 0.4 to 0.5 and with differential improvement in ORR typically >30%. Furthermore, STEPP analysis of TFI (on the MONARCH 3 pts who had received adjuvant ET) demonstrated that pts who had a shorter TFI had a worse prognosis and received relatively greater benefit from abemaciclib plus NSAI than did pts with a longer TFI. Patients with bone-only disease or a long TFI also received benefit from abemaciclib, but to a relatively lesser extent (HR ranging from approximately 0.6 to 0.8). Conclusions: This exploratory analysis of the preplanned final PFS data from MONARCH 3 confirms previous findings that pts with poor prognostic factors may receive relatively greater benefit from the addition of abemaciclib to ET. Citation Format: Joyce O'Shaughnessy, Matthew P. Goetz, George W. Sledge, Miguel Martin, Yong Lin, Tammy Forrester, Ian C. Smith, Angelo Di Leo, Stephen Johnston. The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT099.